Measuring percent change in total flux (photons/s) through in vivo imaging showed that, on day 35 post-injection, mice with the Casc4 KD tumors exhibited decreased tumor burden, compared to those injected with the shCTRL cells (Fig. 5C, D). The gene discussed is GOLM2; the disease is neoplasm.